"In biomedical science, China still lags behind the United States and Europe when it comes to fundamental research and conducting clinical trials involving investigators and participants from several countries. But the nation is now a global leader when it comes to drug development and manufacturing. And it is becoming increasingly important in frontier science. Industry analysts estimate that China now accounts for 70-95% of the global supply chain for many essential pharmaceutical products, including ibuprofen and paracetamol."
"Last December, the US Biosecure Act was signed into law in response to concerns about national security. This act prevents US pharmaceutical companies that receive federal funding from working with certain Chinese biotech companies. Such increased outside scrutiny, stemming from ongoing concerns about how genetic and clinical information is handled in China, has been prompting Chinese government officials, state-affiliated think tanks and industry stakeholders to advocate for building a closed 'secure' biotech ecosystem in China."
China lags behind the United States and Europe in fundamental biomedical research and in multinational clinical trials, but it leads globally in drug development, manufacturing and growing frontier science. China supplies an estimated 70–95% of the global supply chain for many essential pharmaceuticals such as ibuprofen and paracetamol. In 2024, Chinese firms developed over 1,250 new drugs, approaching the US total. China’s share of commercial clinical trials rose from 9% in 2018 to about one-fifth today, and several therapeutic milestones were reached. Rising geopolitical scrutiny, exemplified by the US Biosecure Act, and proposals for a closed 'secure' biotech ecosystem could hinder collaboration and access to medicines.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]